Integrated dmpk and toxicology profiling of ncats/TDB medicinal chemistry lead candidates
Active Awarded Last action
- Contract number
- 75N91026F00026
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,683,296
Award facts
- Contract value 100% obligated
- $1,683,296.00 Current and potential, with all options
- Completion date 2% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 28, 2026, with a ceiling value of $1,683,296 for integrated DMPK and toxicology profiling of NCATS/TDB medicinal chemistry lead candidates. The order is cost-plus-fixed-fee and reaches ultimate completion on September 27, 2031.
Place of performance is Frederick, MD 21702. Leidos Biomedical Research operates as an FFRDC contractor delivering biomedical research and facilities support to the National Institutes of Health. The company's biomedical research capability portfolio spans research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing including monoclonal antibodies, gene therapy vector manufacturing, and vaccine platform development. Leidos Biomedical Research maintains a workforce of approximately 1,830 FTEs and engages a network of subcontractors including Abbott Molecular Inc., Tecan U.S. Inc., Bio-Rad Laboratories, and academic partners such as Stanford University and the University of Pittsburgh for specialized research activities.
Quick answers
Who was awarded contract 75N91026F00026?
75N91026F00026 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2026.
How much is contract 75N91026F00026 worth?
The government has obligated $1,683,296 on 75N91026F00026.
Which agency awarded contract 75N91026F00026?
National Cancer Institute (National Institutes of Health) awarded 75N91026F00026, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91026F00026 an order under another contract?
Yes. 75N91026F00026 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91026F00026 competed?
The extent of competition for 75N91026F00026 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award